Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility: HELP
Articles by Anne-Sophie Gremeau
Based on 9 articles published since 2008
||||

Between 2008 and 2019, A-S Gremeau wrote the following 9 articles about Infertility.
 
+ Citations + Abstracts
1 Guideline [Management by assisted reproductive technology in women with endometriosis: CNGOF-HAS Endometriosis Guidelines]. 2018

Chauffour, C / Pouly, J-L / Gremeau, A-S. ·Département de gynécologie-obstétrique et de reproduction humaine, CHU Estaing, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France. Electronic address: candicechauffour@gmail.com. · Département de gynécologie-obstétrique et de reproduction humaine, CHU Estaing, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France. ·Gynecol Obstet Fertil Senol · Pubmed #29523480.

ABSTRACT: Should the presence of endometriosis change the management of assisted reproductive technology? There is no difference in pregnancy rate after IVF between an agonist or antagonist protocol in patients with endometriosis, so the choice between one or the other of these protocols is free. But the review of the literature has shown an improvement in the chances of pregnancy in case of prolonged ovulation suppression before stimulation for IVF with a GnRH agonist analogue or with oral contraception, especially in cases of severe endometriosis. Endometriosis, regardless of the stage and type of lesions, would have no effect on the IVF results in terms of pregnancy rate and live birth rate, but with a lower number of oocytes collected, especially in cases of severe endometriosis. In a context of superficial endometriosis without pain and of infertility, surgical treatment of superficial endometriosis is not recommended just to increase the chances of pregnancy in IVF. Surgery may have a place in case of failure of IVF to improve the results of the ART. In case of recurrence of endometriosis, surgery is not better than IVF, a medico-surgical concertation is recommended. In addition, studies on ovulation stimulation for IVF do not show any aggravation of the symptoms associated with endometriosis lesions, or an acceleration of its progression, or an increase in the rate of recurrence of the disease.

2 Editorial [Information to patients in endometriosis: We must stop the frightening machine!] 2016

Canis, M / Curinier, S / Campagne-Loiseau, S / Kaemerlen Rabischong, A G / Rabischong, B / Pouly, J L / Grémeau, A S / Botchorishvili, R / Bourdel, N. ·Department of gynecologic surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr. · Department of gynecologic surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. ·Gynecol Obstet Fertil · Pubmed #27765429.

ABSTRACT: -- No abstract --

3 Editorial [Ovarian endometriomas: No-surgery has never been evaluated and surgery correctly performed should remain the gold-standard!] 2016

Canis, M / Botchorishvili, R / Bourdel, N / Chauffour, C / Gremeau, A-S / Rabischong, B / Campagne, S / Pouly, J-L / Matsuzaki, S. ·Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr. · Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. ·Gynecol Obstet Fertil · Pubmed #27751749.

ABSTRACT: -- No abstract --

4 Review Pelvic adhesions and fertility: Where are we in 2018? 2018

Canis, M / Botchorishvili, R / Bourdel, N / Gremeau, A-S / Curinier, S / Rabischong, B. ·Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie et Raymond Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr. · Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie et Raymond Aubrac, 63000 Clermont-Ferrand, France. ·J Visc Surg · Pubmed #29784584.

ABSTRACT: Peritoneal adhesions remain a major public health problem despite the development of laparoscopy. The rules of microsurgery must be known and followed during any pelvic surgery, even in patients who no longer have a desire for pregnancy. Anti-adhesion products are numerous. All have interest, confirmed by anatomical studies showing a smaller extent or a lesser severity of adhesions associated with their use. No studies, however, show clinical benefit in terms of improved pain or postoperative fertility. Pneumoperitoneum parameters, humidification, and lower abdominal pressure should be optimized to limit peritoneal trauma. Peri-operative corticosteroids, whose benefit has been has been demonstrated in at least one randomized trial, should be systematically used.

5 Clinical Trial Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. 2014

Pons-Rejraji, Hanae / Brugnon, Florence / Sion, Benoit / Maqdasy, Salwan / Gouby, Gerald / Pereira, Bruno / Marceau, Geoffroy / Gremeau, Anne-Sophie / Drevet, Joel / Grizard, Genevieve / Janny, Laurent / Tauveron, Igor. ·CHU Clermont Ferrand, Laboratoire de BDR: AMP-CECOS, F-63003 Clermont-Ferrand, France. hpons-rejraji@chu-clermontferrand.fr. ·Reprod Biol Endocrinol · Pubmed #25016482.

ABSTRACT: BACKGROUND: Recommendations for cardiovascular disease prevention advocate lowering both cholesterol and low-density lipoprotein cholesterol systemic levels, notably by statin intake. However, statins are the subject of questions concerning their impact on male fertility. This study aimed to evaluate, by a prospective pilot assay, the efficacy and the toxicity of a decrease of cholesterol blood levels, induced by atorvastatin on semen quality and sexual hormone levels of healthy, normocholesterolaemic and normozoospermic men. METHODS: Atorvastatin (10 mg daily) was administrated orally during 5 months to 17 men with normal plasma lipid and standard semen parameters. Spermatozoa parameters, accessory gland markers, semen lipid levels and blood levels of gonadal hormones were assayed before statin intake, during the treatment, and 3 months after its withdrawal. RESULTS: Atorvastatin treatment significantly decreased circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol concentrations by 42% and 24% (p<0.0001) respectively, and reached the efficacy objective of the protocol. During atorvastatin therapy and/or 3 months after its withdrawal numerous semen parameters were significantly modified, such as total number of spermatozoa (-31%, p<0.05), vitality (-9.5%, p<0.05), total motility (+7.5%, p<0.05), morphology (head, neck and midpiece abnormalities, p<0.05), and the kinetics of acrosome reaction (p<0.05). Seminal concentrations of acid phosphatases (p<0.01), α-glucosidase (p<0.05) and L-carnitine (p<0.05) were also decreased during the therapy, indicating an alteration of prostatic and epididymal functions. Moreover, we measured at least one altered semen parameter in 35% of the subjects during atorvastatin treatment, and in 65% of the subjects after withdrawal, which led us to consider that atorvastatin is unsafe in the context of our study. CONCLUSIONS: Our results show for the first time that atorvastatin significantly affects the sperm parameters and the seminal fluid composition of healthy men.

6 Article Cryopreservation of ovarian tissue in pediatric patients undergoing sterilizing chemotherapy. 2016

Chambon, Fanny / Brugnon, Florence / Grèze, Victoria / Grémeau, Anne-Sophie / Pereira, Bruno / Déchelotte, Pierre / Kanold, Justyna. ·a Centre Régional De Cancérologie Et Thérapie Cellulaire Pédiatrique, Hôpital Estaing , Clermont-Ferrand , France ; · b INSERM-CIC 1405, Unite CRECHE , Clermont-Ferrand , France ; · c Faculté De Médecine, Clermont Université, Université Clermont1 , Clermont-Ferrand , France ; · d CHU Clermont-Ferrand, Assistance Médicale À La Procréation, CECOS, CHU Clermont-Ferrand , Clermont-Ferrand , 63001 , France ; · e Laboratoire Génétique Reproduction Et Développement, Université D'auvergne , INSERM U1103 , Clermont-Ferrand , France ; · f CHU De Clermont-Ferrand, Unité De Biostatistiques, Délégation À La Recherche Clinique Et L'innovation , Clermont-Ferrand , France ; · g Service D'anatomopathologie, Hôpital Estaing , Clermont-Ferrand , France. ·Hum Fertil (Camb) · Pubmed #27008573.

ABSTRACT: Significantly improved survival rates in children and adolescents with cancer have put fertility preservation high on the pediatric oncology agenda. Here we report a retrospective single-center study of 13 years experience of ovarian tissue cryopreservation (OTC) before sterilizing treatment in order to define the safety/benefits of OTC and study clinical/hormonal outcomes in girls. From 2000 to 2013, OTC was performed in 36 girls: eight had non-malignant disease and 28 had malignant disease. Laparoscopy was used to collect a third of each ovary that was frozen by a slow cooling protocol. Indications for OTC were 13 auto-, 19 allo-stem-cell-transplantation and 4 sterilizing chemotherapy. Ovarian tissue harvested by intraumbilical laparoscopy led to no major postoperative complications and did not delay chemotherapy. Histological analysis of ovarian tissue showed an average of 9 primordial follicles/mm(2) [0-83] and no malignant cells were identified. Median post-harvest follow-up was 36 months [1-112]: 26 girls were alive in complete remission and 10 had died. Hormonal results were evaluable for 27 patients (median age 17 yrs [5-26]): 16 patients were in premature ovarian insufficiency. OTC sampling one third of each ovary appears to be an appropriate approach to preserve fertility in children without consequences on subsequent therapeutic program.

7 Article [Adverse pregnancy outcomes after Assisted Reproduction Technology in women with endometriosis]. 2014

Carassou-Maillan, A / Pouly, J-L / Mulliez, A / Dejou-Bouillet, L / Gremeau, A-S / Brugnon, F / Janny, L / Canis, M. ·Pôle gynéco-obstétrique-reproduction humaine, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 1, France. Electronic address: ananda_carassoumaillan@yahoo.fr. · Pôle gynéco-obstétrique-reproduction humaine, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 1, France. · Département d'information médicale, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France. ·Gynecol Obstet Fertil · Pubmed #24679602.

ABSTRACT: OBJECTIVE: While association between endometriosis and infertility is well established, there are few studies about the impact of endometriosis on adverse pregnancy outcomes. The aim of this study was to determine the effect of endometriosis on obstetric outcomes and whether the severity of the disease had an influence on these. PATIENTS AND METHODS: We performed a retrospective study to investigate the obstetric outcomes of a population of 1204 subfertile women, including 258 with endometriosis, who obtained, thanks to assisted reproduction technology, a singleton pregnancy evolving beyond embryonic stage. Two analyzes were performed. The first compared women with endometriosis to women with other causes of infertility. The second observed adverse pregnancy outcomes according to AFS-R stages of endometriosis. RESULTS: The overall rate of live birth children was 95.8%. In case of endometriosis, there was a significant increase of the incidence of preterm delivery, especially before 32 weeks amenorrhea (6.2% vs 3.1% in the group "without endometriosis", P = 0.03), antenatal bleeding (5.3% vs 2.2%, P = 0.01) and placenta previa (4.9% vs 0.9%, P < 0.0001). The incidence of gestational diabetes was significantly decreased (0.4% vs 2.7%, P = 0.04). There was no correlation between endometriosis and cesarean section or preeclampsia, or between the AFS-R stage and adverse pregnancy outcomes. DISCUSSION AND CONCLUSION: Endometriosis is a factor of obstetrical risk, independently of the infertility it causes. The AFS-R score does not seem to be representative of obstetric outcomes beyond first trimester of pregnancy for women with endometriosis.

8 Article [Ovarian drilling by fertiloscopy: feasibility, results and predictive values]. 2013

Pouly, J-L / Krief, M / Rabischong, B / Brugnon, F / Gremeau, A-S / Dejou, L / Fabre, N / Mage, G / Canis, M / Folini, X. ·Service de gynécologie, pôle de gynécologie, obstétrique et reproduction, CHU de Clermont-Ferrand, CHU d'Estaing, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France. jlpouly@chu-clermontferrand.fr ·Gynecol Obstet Fertil · Pubmed #23566682.

ABSTRACT: OBJECTIVES: The aims of this study were to assess the effectiveness of the ovarian drilling, compare the techniques by fertiloscopy or by laparoscopy, and search for prognostic factors of success. PATIENTS AND METHODS: This retrospective study focused on 154 ovarian drilling carried out between June 1998 and December 2010 where the drilling has been proposed after failure of the clomifene and before stimulation by FSH among PCOS patients. RESULTS: The post-drilling ovulation rate is 62%. The spontaneous on-going pregnancy rate is 31% and the total pregnancy rate scalable including secondary stimulation is 58%. No significant difference was found between laparoscopy and the fertiloscopy. The peroperative complications in fertiloscopy were more frequent but without consequences and 20% of the fertiloscopy had to be converted to laparoscopy, half of them for complications and half of them for technical difficulties. The only found preoperative predictors of success are an euthyroidy that increases the chances of pregnancy in general (including the side stimulation) and a lower FSH levels. However, it appears that the chances of pregnancy in FSH stimulation are dramatically decreased if the drilling did not induce ovulation versus the cases where it induced ovulation but no pregnancy (28.8% versus 58.1%, P<0.003). DISCUSSION AND CONCLUSION: Fertiloscopy results are comparable with those of laparoscopy, which suggests an advantage to this technique in terms of cost, comfort, and length of hospital stay. No usable in practice patient selection criteria could be highlighted. The study suggests that the absence of ovulation after drilling may be a direct indication for IVF.

9 Article In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. 2012

Gremeau, Anne-Sophie / Andreadis, Natasha / Fatum, Muhammad / Craig, Jo / Turner, Karen / McVeigh, Enda / Child, Tim. ·Oxford Fertility Unit, Institute of Reproductive Sciences, Oxford, United Kingdom. asgremeau@hotmail.com ·Fertil Steril · Pubmed #22658347.

ABSTRACT: OBJECTIVE: To compare the outcome of unstimulated in vitro maturation (IVM) and routine IVF/intracytoplasmic sperm injection (ICSI) for women with polycystic ovaries (PCO). DESIGN: Retrospective case-control study. SETTING: Fertility unit. PATIENT(S): Ninety-seven patients undergoing IVM were compared with 97 patients undergoing IVF. All had PCO and matched for age, infertility diagnosis, and ovulatory status. INTERVENTION(S): In vitro maturation cycles were unstimulated and hCG was administered 35-40 hours before oocyte retrieval. Oocytes were matured in vitro for 24-48 hours before insemination by ICSI. Endometrial priming with E(2) and P was commenced from the day of egg retrieval and one to two embryos were transferred on days 2-5 of development. Standard long protocol IVF/ICSI was used in the control group. MAIN OUTCOME MEASURE(S): Live birth rate per cycle and ovarian hyperstimulation syndrome (OHSS) rate. RESULT(S): Overall, 65% of IVM eggs matured in vitro in the IVM group. Implantation rates were significantly higher in the IVF group (19.4% vs. 12.9%) as clinical pregnancy rates (50.5% vs. 19.6%) and live birth rates (44.3% vs. 16.5%) than in the IVM group. The OHSS rate was significantly higher in the IVF group (8.2% vs. 0%). CONCLUSION(S): In vitro maturation is a safer and simpler alternative to conventional IVF for women with PCO. It avoids difficulties of gonadotropin stimulation and the risk of OHSS but has a significantly lower live birth rate. Current research projects aim to close the success gap between IVM and IVF.